All posts by imreal

Multi-Omics and Multimodal Data Integration and Analysis on AWS, Upcoming Webinar Hosted by Xtalks


The featured speakers will cover strategies to transform, manage and analyze research-ready multimodal data using an AWS data lake.

Modern clinical research projects may include data from multiple modalities for a single patient, including genomic, clinical and imaging data. The challenge that organizations and researchers face is that these data types are often stored in different formats and locations, so bringing them together to perform analysis is a time-consuming task. In this webinar, the featured speakers will cover strategies to transform, manage and analyze research-ready multimodal data using an AWS data lake.

Join this webinar to learn more about multi-omics and multimodal data integration and analysis.

Join Adam Kraut, Senior Director, Architecture, BioTeam; Nick George, Scientific Consultant, BioTeam; and Sujaya Srinivasan, Genomics Solutions Architect, Global Healthcare, AWS, for the live webinar on Monday, September 26, 2022, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Multi-Omics and Multimodal Data Integration and Analysis on AWS.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

American Parkinson Disease Association Supports Researchers With $2.35 Million in New Funding


“The work being done as a result of the grants in this new funding cycle will have an incredible impact on the world of PD.” — Leslie A. Chambers, President & CEO, APDA

The American Parkinson Disease Association (APDA) has just awarded $2.35 million to support cutting-edge Parkinson’s disease (PD) research for the 2022-2023 funding year – an increase of more than 25 percent from the prior year. The funded research projects will explore a range of important and innovative topics including: understanding the molecular underpinnings of anxiety in PD, probing the role of DNA damage in genetic mutations in PD, testing of augmented reality in the treatment of freezing of gait, and more. APDA focuses on investing in the most promising clinicians and scientific projects focused on discovery of the cause(s) and finding the cure(s) for Parkinson’s disease (PD) and has been a funding partner in many major PD scientific breakthroughs since the organization began.

With someone diagnosed with PD every nine minutes, this research is critical as we push for better treatments and ultimately, a cure. APDA is steadfast in its research focus – identifying and supporting researchers early in their careers to encourage them to either commence or continue dedicating themselves to PD research, as well as helping established investigators pursue new and novel ideas. Leslie A. Chambers, President & CEO of APDA comments, “Part of APDA’s tagline is ‘hope in progress’ and it’s so rewarding to support our researchers as they develop their theories and obtain significant pilot data and initial proof of concept. This initial data often allows them to apply for and receive larger grants from the National Institutes of Health and other funding institutions.” Chambers continues, “Without the initial support from APDA, some research projects might never get off the ground. We’re proud to help make that progress happen and provide hope to everyone impacted by PD.”

Grants for the year ahead have been awarded in the form of four Post-Doctoral Fellowships, thirteen Research Grants, one Diversity in Parkinson’s Disease Research grant, eight APDA Centers for Advanced Research, and one George C. Cotzias Memorial Fellowship, APDA’s most prestigious award.

For the third year in a row, APDA is awarding a specialized grant to a researcher focused on diverse and under-represented communities. APDA created the first-of-its-kind Diversity in Parkinson’s Disease Research Grant in 2019 to encourage and support researchers who are committed to diversity-focused research so we can learn more about how the disease affects different populations and ultimately better serve people with PD from all communities.

All APDA grants are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board (SAB) which is comprised of scientists with a wide array of backgrounds and expertise in all areas relevant to PD research. The SAB meets annually to review all grant proposals and set the scientific direction of APDA’s annual research investment. “As always, it is an incredibly challenging decision-making process, and the SAB has to make very tough choices” states Rebecca Gilbert, MD, PhD, and Chief Scientific Officer, APDA. “Thanks to the generosity of our donors, we were thrilled to be able to fund even more research this year, enabling us to say yes to some really innovative projects and promising researchers.” (Meet some of the researchers in this video.)

The 2022-2023 APDA Research Grants

The George C. Cotzias Fellowship is APDA’s most prestigious grant and is awarded to a young physician-scientist with exceptional promise who is establishing a career in research, teaching, and clinical services relevant to Parkinson’s. The award spans three years and is designed to fund a long-range project focused on PD. This year’s awardee is:


  • Gary Ho, MD, PhD — Brigham and Women’s Hospital, Boston MA (Leveraging protein palmitoylation to correct vesicle trafficking defects in Parkinson


disease)

APDA Diversity in Parkinson’s Disease Research Grants are one-year grants to study the health inequities and/or differences among under-studied PD communities, across the spectrum of ethnicity, ancestry, geography, socioeconomic conditions, and gender. This year’s awardee is:

  • Erin Foster, PhD — Washington University, St, Louis, MO (Understanding engagement in research, clinical care, and community services among people of color with Parkinson disease)

Post-Doctoral Fellowships are awarded to support post-doctoral scientists who recently completed their PhD work and whose research holds promise to provide new insights into the pathophysiology, etiology, and treatment of PD. This year’s awardees are:

  • Tyler Camp, PhD — University of Illinois Urbana-Champaign, Champaign, IL (Alpha-synuclein oligomerization and membrane localization in Parkinson’s disease)
  • Stephan Grimaldi, PhD — Massachusetts General Hospital, Boston, MA (Longitudinal changes of brainstem-based biomarkers of prodromal Parkinson’s disease with Ultra-High Field MRI)
  • Anastasia Kuzkina, PhD — Brigham and Women’s Hospital, Boston, MA (Developing human IPSC models for examining host-strain interactions in synucleinopathy)
  • Andrew Zimnik, PhD — Columbia University, New York, NY (Role of basal ganglia output in acquiring and executing complex motor skills)

Research Grants are awarded to investigators performing innovative PD research at major academic institutions across the United States. This year’s awardees are:

  • Eamonn Dickson, PhD — University of California, Davis. Davis, CA (Alpha-synuclein dependent remodeling of membrane contact sites as a driver of Parkinson’s Disease neurotoxicity.)
  • Ronald Emeson, PhD — Vanderbilt University, Nashville, TN (ADAR-Mediated LRRK2 Therapeutics in Parkinson’s Disease)
  • Sunil Kumar, PhD — University of Denver, Denver, CO (Therapeutic Validation of Novel Targets Associated with Parkinson’s Disease)
  • Gabsang Lee, PhD — Johns Hopkins University School of Medicine, Baltimore, MD (In vitro and in vivo efficacy of hit compound selected from OASIS drug screening platform)
  • James Liao, PhD — Cleveland Clinic, Cleveland, OH (External vs internal-triggered augmented-reality visual cues to treat freezing of gait)
  • Michael Lodato, PhD — University of Massachusetts Chan Medical School, Worcester, MA (Single-cell whole genome sequencing analysis of DNA damage and somatic mutation in the human Parkinson’s disease brain)
  • Ryan Roemmich, PhD — Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD (An automated mHealth approach for video-based motor assessment in Parkinson’s disease)
  • Hiroaki Sekiya, MD, PhD — Mayo Clinic Jacksonville. Jacksonville, FL (Differential protein and gene expression by digital spatial profiling in neurons with synuclein oligomers or Lewy bodies)
  • Martine Tetreault, PhD — Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada (Regulation of aberrant immunity in Parkinson’s disease by Stearoyl-CoA Desaturase)
  • Nicolas Tritsch, PhD — New York University School of Medicine, New York, NY (Revealing how striatal circuits gradually change as dopamine neurons degenerate)
  • Hisashi Umemori, MD, PhD — Boston Children’s Hospital, Boston, MA (The nigrostriatal-specific dopaminergic synapse organizer and Parkinson’s disease)
  • Laura Volpicelli-Daley, PhD — University of Alabama at Birmingham, Birmingham, AL (mGluR4 activation to rescue amygdala defects caused by aggregated alpha-synuclein)
  • Scott Waldman, MD, PhD — Thomas Jefferson University, Philadelphia, PA (Targeting GUCY2C for Neuroprotection in Experimental Parkinson’s Disease)

In addition, continued funding was granted for eight APDA Centers for Advanced Research to support various programs including research trainees, clinical fellowship programs, early-stage discovery programs and later-stage clinical translation. These Centers facilitate research which is at the forefront of investigation into the causes, treatments and ultimately cure for PD. The current APDA Centers for Advanced Research are:

  • Boston University School of Medicine, Boston, MA
  • Emory University School of Medicine, Atlanta, GA
  • Mayo Clinic, Jacksonville, FL
  • Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
  • The Brigham and Women’s Hospital, Boston, MA
  • University of Alabama at Birmingham School of Medicine, Birmingham, AL
  • University of Pittsburgh Medical Center, Pittsburgh, PA
  • Washington University School of Medicine, St. Louis, MO

“The work being done as a result of the grants in this new funding cycle will have an incredible impact on the world of PD,” states Chambers. “This work is only possible because of the steadfast support of our generous APDA donors.”

Learn more about these grantees and the exciting work they are doing and browse all APDA-funded research by visiting http://www.apdaparkinson.org/research/what-we-fund/.

Researchers and physicians who are interested in applying for APDA funding can visit http://www.apdaparkinson.org/research for details on the 2023-2024 funding opportunities. Letters of Intent for the 2023-2024 grant cycle can be submitted starting September 28, 2022 with a deadline of December 2, 2022.

Those who want to support APDA’s critical research with a donation can do so by visiting http://www.apdaparkinson.org and clicking the DONATE button or mailing a check payable to APDA to: APDA, PO Box 61420, Staten Island, NY 10306.

The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to help the more than one million people in the United States with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $226 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson’s disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as our national Research Program and Centers for Advanced Research, please visit us at http://www.apdaparkinson.org.

                                                                                                 # # #

Share article on social media or email:

XinThera Announces Appointment of Christopher LeMasters as Chief Executive Officer


The rapid advancement of the company’s goals and strategic initiatives is evidence of such leadership…

XinThera, Inc., a drug discovery company focused on building a small molecule oncology and immunology pipeline, today announced that its Board of Directors has appointed Christopher LeMasters as the company’s first Chief Executive Officer. LeMasters, who has served as the company’s EVP and Chief Operating Officer since October 2021, was also appointed to XinThera’s Board of Directors. Additionally, in the wake of the passing of the company’s founder, Stephen Kaldor, Ph.D., the board elected Qing Dong, Ph.D., the company’s co-founder and Chief Scientific Officer, as Chairman of the Board.

“These changes reflect the Board’s confidence in the leadership and commitment both Chris and Qing have demonstrated during their tenure at XinThera,” said Michael Rome, Ph.D., member of XinThera’s Board of Directors and managing director of Foresite Capital. “The rapid advancement of the company’s goals and strategic initiatives is evidence of such leadership, and I look forward to continuing to support this exceptional management team and company.”

About Christopher LeMasters, CEO of XinThera, Inc.

Over his 30-year career, Mr. LeMasters has co-founded and served as a management team member for multiple biotechnology companies. Prior to serving as COO of XinThera, he was COO of Amplyx Pharmaceuticals, where he led the strategic efforts that resulted in the company’s successful sale to Pfizer in April 2021. From 2016 to 2020, Mr. LeMasters was EVP & CBO of Mirati Therapeutics, where he was responsible for corporate development, strategy, and investor relations. He also served as the CEO of Promosome, a privately held mRNA re-engineering company, and as CBO at Conforma Therapeutics, Cabrellis Therapeutics, and Tragara Pharmaceuticals. Earlier in his career, he worked in the corporate business development group at Eli Lilly & Company and as a management consultant with Coopers & Lybrand and Owens-Corning.

Mr. LeMasters holds a BS in Finance from Indiana University and an MBA from the University of Chicago.

About Qing Dong, Ph.D., co-founder, and CSO of XinThera, Inc.

Mr. Dong is a passionate drug hunter with more than 25 years of experience in drug discovery. He has particular strength in the structure-based design of oncology and inflammation drug candidates and has contributed to five marketed drugs and more than 15 clinical phase compounds. Prior to co-founding XinThera in 2021 along with Stephen Kaldor, Ph.D., and Gene Hung, M.D., he co-founded small molecule inflammation biotech FronThera in 2015 and served as its President & CSO through its successful acquisition in February 2021. From 2010 to 2015, Mr. Dong was CSO at Hengrui and played an integral role in building this leading Chinese pharmaceutical company’s small molecule portfolio. Earlier in his career, he worked as a medicinal chemist at both Takeda and Triad Therapeutics.

Mr. Dong received his Ph.D. in organic chemistry at Rice University and completed his post-doctoral training at Harvard Medical School.

About XinThera, Inc.

XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. Its lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with best-in-class potential in areas of high-unmet need. For more information, please visit http://www.xinthera.com.

Contact:

Mary Gieson

Sr. Director Corporate Operations

XinThera, Inc.

mgieson@xinthera.com

Share article on social media or email:

Breakthrough App Uses the Power of AI to Make it Easier to Hear Speech in Background Noise


HeardThat Logo

Singular Hearing, a subsidiary of Singular Software and creator of HeardThat, today announced the full release of its HeardThat app for iOS and Android. HeardThat uses the power of smartphones to run sophisticated artificial intelligence (AI) algorithms that separate speech and noise, empowering users to hold clear and effortless conversations in places with background noise, like restaurants, coffee shops, grocery stores, and family gatherings. As a software-only app, no new devices are required. HeardThat works with the devices most people already have, including most Bluetooth-enabled hearing aids, cochlear implants, and ordinary earbuds and headphones.

Since HeardThat’s early release, the company’s AI experts have worked tirelessly with users to improve ease of use, recognize more types of noise, and work with more devices. Testing by National Research Council Canada showed a significant improvement in objective measures of intelligibility and listening effort. The app also gained a loyal following of thousands of regular users, with its most active user base growing by 12% month-over-month.

The difficulty of understanding speech in noise impacts people across a wide range of hearing abilities and is common among the aging population. Previous hearing-assistive devices and apps have not effectively addressed background noise. As a result, those that have trouble hearing conversations in loud places tend to avoid noisy social scenarios, which can lead to isolation and cognitive decline. The emergence of AI algorithms capable of being run on smartphones opens more opportunities for improving accessibility technologies.

“The ability to hear speech in noise is one of the first signs of hearing decline. It’s also the most desired feature users of hearing aids or other hearing-assistive wearables request,” said Singular Hearing founder and CEO Bruce Sharpe. “HeardThat users regularly share the positive impact our app has made on their lives and we’re proud to offer a solution that enables understandable conversations with less effort.”

“I have a lot of trouble in noisy situations, even hearing the people next to me. I have the latest and greatest hearing aids, but they don’t increase understanding in noisy environments,” said one user. “HeardThat’s technology is pretty amazing. I never use the amplifier feature on my phone because it just doesn’t work the way that HeardThat does.”

With the full release, new and current users can access HeardThat for a one-month free trial period. They can then choose to subscribe to the app for $9.99 USD per month (or $99.99 USD per year) or use the free tier, which provides users with 30 minutes of app time per week. For more information on HeardThat, please visit heardthat.ai.

About Singular Hearing

Singular Hearing is a subsidiary of Singular Software. Founder and CEO Bruce Sharpe and his team of AI experts have extensive experience in audio technology and a deep passion for finding effective solutions to everyday problems. They leverage machine learning and speech processing to create innovative products that help people live better by hearing better.

Singular Hearing is the creator of HeardThat, an award-winning innovative app that turns smartphones into sophisticated hearing-assistive devices. HeardThat helps those with hearing challenges by delivering clear speech in noisy environments.

HeardThat won the What’s Next Innovation Challenge Sponsored by AARP Innovation Labs at the 17th Annual What’s Next Longevity Venture Summit and was named the first runner-up in the What’s Next Business Plan Competition at the 17th What’s Next Longevity Venture Summit. For more information, please visit heardthat.ai.

###

Share article on social media or email:

Blue Zones Discoverer Dan Buettner to Keynote at the 2022 Global Wellness Summit


Dan’s work on how total environment and culture are the lynchpins of longevity is increasingly changing the way the world thinks about health, wellness, prevention and aging

The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, today announced that Dan Buettner, who famously identified the Blue Zones–those five places around the world where people live significantly better, longer lives–will keynote at the conference being held in Tel Aviv, Israel from October 31 to November 3. Buettner is an explorer, a National Geographic Fellow, an award-winning journalist and producer, and the author of four runaway bestsellers. His new book, “Blue Zones American Kitchen,” which uncovers the traditional roots of plant-forward cuisine in the US, will be released in December. A four-part documentary series on lessons from the Blue Zones will premiere in early 2023.

Since 2004, Buettner has been researching Blue Zone communities (in Sardinia, Italy; Okinawa, Japan; Nicoya, Costa Rica; Ikaria, Greece; and Loma Linda, California) to understand what keeps people thriving and healthy to age 100. His discovery: their longevity has nothing to do with self-discipline, or complex health and fitness regimes. Instead, it’s these communities’ holistic ecosystems that make the healthy choice the easy one: Residents are naturally “nudged” toward daily movement, a plant-based diet, strong social connections, and a sense of purpose.

New research on longevity diets: At the Summit, he will present his latest research on what the world’s longest-lived people eat and the eye-opening impact that diet has on longevity. He will share surprising insights from his new “Blue Zones American Kitchen,” which uncovers the regions and cultures that have shaped America’s healthiest food landscapes. These include some of the most under-recognized plant-forward communities, from Hmong elders in Minnesota to Quakers in New England. Buettner will explore how a restoration of these specific, traditional healthy eating subcultures around the world could save us trillions of dollars a year in healthcare costs.

“Dan wowed delegates at the 2018 Summit and we’re thrilled to have him share his latest research this year. His work on how total environment and culture are the lynchpins of longevity is increasingly changing the way the world thinks about health, wellness, prevention and aging. And it’s also having a growing impact on public policy, wellness community design, and longevity science, all big topics at this year’s conference,” said Susie Ellis, GWS chair and CEO.

“The overwhelming finding from my years of research is that the path to a long and happy life is not about changing your habits, it’s about changing your surroundings. Leaders in public policy, architecture and design, wellness real estate, and hospitality that will gather at the conference now have the greatest opportunity to architect communities and environments so that people’s daily decisions are naturally the healthy ones,” said Buettner. “I’m so happy to return to the Summit. I’ve given thousands of speeches in the last decade and I rarely return to a conference, but I had more fun at the GWS in Italy than I’ve had at any conference ever.”

Longevity Science–A Key Summit Topic: The longevity science market is forecast to reach $600 billion by 2025, and new approaches that can bring unprecedented increases to the quality and length of human lifespans (“healthspans”) have become one of the buzzed-about topics in wellness and medicine. It will be a key focus at this year’s GWS, where Buettner will join medical experts such as Shai Efrati, MD, of Tel Aviv University, who is pioneering medical hyperbaric oxygen treatments shown to reverse the biology of aging, and Tzipora Strauss, MD, who is co-leading a new longevity medicine research center at Israel’s Sheba University.

More about Buettner:

Buettner’s books, “The Blue Zones: Lessons for Living Longer from the People Who’ve Lived the Longest,” “Thrive: Finding Happiness the Blue Zones Way,” “The Blue Zones of Happiness,” and “The Blue Zones Solution: Eating and Living Like the World’s Healthiest People,” were all global bestsellers. He regularly appears on major news programs, including the Today Show, NBC Nightly News and the BBC, and has keynoted at some of the most important global conferences, including the World Economic Forum and Bill Clinton’s Health Matters Initiative. He also holds three Guinness World Records in distance cycling.

Registration for the 2022 Summit is open.

About the Global Wellness Summit —The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor “Reverse Pitch” events and Global Wellness Symposiums. The organization’s annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.

Share article on social media or email:

Catalent Appoints Dr. Wai Lam Ling as Vice President, Scientific Advisory


Wai Lam Ling, Vice President, Scientific Advisory at Catalent

Wai Lam Ling, Vice President, Scientific Advisory at Catalent

We welcome Wai Lam to Catalent, where she will have a pivotal role in leading the company’s scientific advisory team of experts to help innovators, which is unique in our industry.

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the appointment of Wai Lam Ling, Ph.D. as Vice President, Scientific Advisory. Reporting to Julien Meissonnier, Vice President, Chief Scientific Officer, she will join the company’s Science & Technology Leadership team.

Dr. Ling brings with her more than 25 years of experience in R&D and Chemistry, Manufacturing and Controls (CMC) operations across biologics and gene therapies, working for companies including Rocket Pharmaceuticals, Merck & Co (MSD) and Schering-Plough Corporation. She has led the development and regulatory filings of more than 20 biologic therapies, and supported the commercialization of several biologic products, including the cancer treatment, Keytruda®. She holds a bachelor’s degree in biochemistry from the University of California, Los Angeles, and gained a doctorate in pharmacology from Rutgers University before completing her post-doctoral research fellowship at the Albert Einstein College of Medicine, New York.

“We welcome Wai Lam to Catalent, where she will have a pivotal role in leading the company’s scientific advisory team of experts to help innovators, which is unique in our industry, to evaluate and develop the best technologies and formulations to bring their programs, across a range of modalities, to scale with optimal CMC strategies,” said Julien Meissonnier.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 19,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

HomeTown Health hosts 2022 Policy Maker Tour of Rural Healthcare Facilities in Georgia


“we continue to look forward to bringing additional policy makers each opportunity we have to expose as many policymakers as possible to the faces and communities served through rural healthcare throughout this great state.”

HomeTown Health resumed its ‘in-person’ Policy Maker Tours August 16-17, 2022. HomeTown Health has conducted “Policy Maker Tours” since 2010 with a focus on bringing legislators and others from the Atlanta Capitol building onsite in rural hospitals to see the facilities, learn about their challenges, learn about their successes, and get a real-life view of the rural communities served by rural hospitals throughout Georgia. From their experiences on the tour, legislators gain a more robust understanding of the impacts on rural healthcare within the state as well as through the healthcare industry structure at large. Policy Makers get to meet the leaders of rural facilities, put faces with names and facilities and towns, that connect with legislative decisions from the Capitol that impact rural healthcare in Georgia.

Throughout the two days, HomeTown Health took two Chairman Terry England, House Appropriations Committee and Christine Murdock, Deputy Director, House Office of Planning and Budget to rural hospitals. This was Chairman England’s tenth and final tour in his current position and Christine Murdock’s first tour. The driving tour has policy makers together for discussions with each other, the HomeTown team and the rural hospital leaders at each hosting location.

Healthcare facilities participating in the policymaker tour were:

  •     Calhoun Nursing Home, part of the Hospital Authority of Miller County, Edison, Georgia
  •     Miller County Hospital, part of the Hospital Authority of Miller County, Colquitt, Georgia
  •     Memorial Hospital & Manor, Bainbridge, Georgia
  •     Colquitt Regional Medical Center, Moultrie, Georgia
  •     Crisp Regional Hospital, Cordele Georgia

Along the various hospital stops, policymakers were joined by local hospital leaders, board members, authority members and community leaders to listen in and learn more about the challenges and successes of their local facilities.

“It is our goal to provide policy makers a meaningful experience in rural healthcare while also giving our rural healthcare facilities an opportunity to more meaningfully connect with their policymakers,” says HomeTown Health CEO Jimmy Lewis, who serves as the chauffeur for the policy maker tour each year.

In addition to the hospital site visits, this year’s policy maker tour included a stop at Georgia Premium Meats in Colquitt, Georgia – a protein processing center that is looking to expand food service of proteins to hospitals at an affordable price as an alternative to traditional out of state food sourcing companies that are sometimes impacted by market demand and item shortages.

“We are grateful to each policy maker who has ever joined us for a policy maker tour – including Rep. England who has made several of these tours throughout his tenure,” says HomeTown Health CEO Jimmy Lewis. “Rep. England is poised to leave the Capitol this year with his retirement, and we will certainly miss his support and engagement, however, we continue to look forward to bringing additional policy makers each opportunity we have to expose as many policymakers as possible to the faces and communities served through rural healthcare throughout this great state.”

HomeTown Health, LLC, continues to serve rural hospitals throughout the United States after over 20 years. HomeTown Health, LLC offers advocacy, education, business partner services and support, healthcare industry conferences, and strategic support to its member hospitals as well as expansive grant-based resources through key partnerships with the Department of Public Health and Department of Community Health in many states. HomeTown Health, LLC is a network of rural hospitals, healthcare providers, and best practice business partners who collectively pursue ways to help its membership survive in the environment of constant change in reimbursement, operations, and technology. HomeTown Health, LLC is committed to providing legislative representation, best practice solutions, and continuing education and training through research and the continuous improvement of processes for healthcare providers. HomeTown Health’s vision is to support rural healthcare organizations in providing high quality, accessible, and competitive care through a heavily regulated and increasingly technology-dependent environment. HomeTown Health University (HTH’s education department) has a more specific vision to provide continuing education in various live and online formats that is high quality, current, effective, and applicable for its intended audience. Learn more at http://www.hometownhealthonline.com and more about its online education at http://www.hthu.net.

Share article on social media or email:

UpClear Named to Inc. 5000 for the Ninth Consecutive Year


UpClear on Inc 5000 for 9 years

“We have grown into a leader in Revenue Management software for CPG and are among the very few with a global presence. Our growth over the years demonstrates that our client-focused, product-led strategy has paid off.” – Thierry Soudee, Founder & CEO

Global SaaS company UpClear has been awarded a spot on the Inc. 5000 list for the ninth consecutive year, from 2014 through 2022. The recognition pushes the CPG Revenue Management software maker into rarefied territory. According to former Inc. Magazine Editor-in-Chief James Ledbetter, the nine-time listing has only been achieved by 0.5% of Inc. 5000 companies.

Inc. 5000, published by Inc. Magazine, recognizes the fastest growing private companies in the United States based on three-year cumulative growth. In 2021, UpClear maintained its track record of growth through new client adoption of BluePlanner, the company’s software, and extension of capabilities to existing clients. These capabilities include software and services for Trade Promotion Management (TPM), Trade Promotion Optimization (TPO), Integrated Business Planning (IBP) and Revenue Growth Management (RGM). This comes after years of investment in team, R&D, and extensive development of the fifth generation of the platform, BluePlanner 5.

“We are very proud to be on the Inc. 5000 list 9 times in a row. We have grown from a true start-up into a leader in Revenue Management software for the Consumer Packaged Goods (CPG) industry. We are among the very few with a global presence and the excellent reputation that comes with a proven product developed over an extended period of time. Our growth over the years demonstrates that our client-focused, product-led strategy has paid off. As a business, we have always shown resilience through volatile economies, a global pandemic, or competitors’ consolidations. We serve a large addressable market and feel confident about the future. Our recent investments in BluePlanner 5, data science and infrastructure have set the foundation for scalability, and we look to transform our go-to-market and distribution approach with partners to grow the Revenue Management software category and our share of it.” says Thierry Soudee, UpClear Founder and CEO.

UpClear will continue to be a key partner to CPG companies working to make the right decisions to grow profitably when faced with volatility and other market dynamics. Through the BluePlanner platform, they gain faster, more complete visibility into their business.

About UpClear

UpClear makes Revenue Management software used by emerging, growing, and established Consumer Goods brands around the globe. Its BluePlanner platform is an integrated solution supporting Trade Promotion Management, Trade Promotion Optimization, Integrated Business Planning, and Revenue Growth Management. UpClear serves global and regional brands in over 20 countries in North America, Europe, and Asia.

upclear.com

Share article on social media or email:

Viewpoint with Dennis Quaid to Highlight Prostate Cancer in upcoming segments


News Image

The programs will reiterate many of these important points and shed light own the future of prostate cancer treatments.

New Viewpoint with Dennis Quaid episodes will begin covering prostate cancer awareness in September, during Prostate Health month. The programs will feature leading treatments and research developments regarding prostate cancer. Applicable content providers have contributed their expertise for the segments.

Bringing awareness to advances in the medical industry is the type of content Viewpoint with Dennis Quaid is made to highlight. The platform features a wide array of topics in its episodes to enlighten viewers nationwide.

Every year, more than one million men are diagnosed with prostate cancer, and more than 300,000 die from the disease. Cancer makes an appearance when cells in the prostate evolve. When a cell’s DNA changes, it can mean the cells grow and divide more rapidly than normal cells, resulting in cancer.

It is not entirely clear what causes prostate cancer. Experts note that prostate cancer is more common in men after age 50, and those who are obese have a higher risk than those with a healthy weight. Family history may also be a contributing factor.

Treatments for prostate cancer may include radiation therapy, prostate removal surgery, hormone therapy, chemotherapy, freezing or heating prostate tissue, immunotherapy, and targeted drug therapy. Medical professionals recommend maintaining a healthy weight, exercising regularly, and consuming a nutritious diet rich in fruits and vegetables to help prevent disease development.

The programs will reiterate many of these important points and shed light own the future of prostate cancer treatments. Actor Dennis Quaid will host the episodes.

Viewpoint with Dennis Quaid is created for distribution purposes across television stations. The informational segment is the recipient of numerous Telly awards. A diverse team of editors and producers develop the show.

Share article on social media or email:

Stratosphere Networks Sponsors Trilogy’s Changing Lives Event


Stratosphere Networks logo.

Trilogy does incredibly vital work for people living with mental illness in the Chicago community, and we’re happy to help in any way we can.

Stratosphere Networks has announced it will sponsor Trilogy Behavioral Healthcare’s Changing Lives event on September 29, 2022, at Venue West at 221 N. Paulina St. in Chicago. The event will commemorate the non-profit care provider’s anniversary and over 50 years of mental wellness.

The evening will begin with a VIP cocktail reception at 5:30 p.m. The Changing Lives event will officially kick off at 6:30 p.m. Attendees will enjoy drinks, savory bites, and sweet desserts as they celebrate the positive impact of Trilogy’s services, thanks to donors and supporters.

For over 50 years now, Trilogy has helped people in Chicago and beyond recover from mental illness by providing ongoing support and essential services. The organization’s mission is to deliver comprehensive, integrated care that enables individuals recovering from mental illness to lead independent and meaningful lives.

“We’re proud to sponsor the Changing Lives event,” said Kevin Rubin, president and CIO of Stratosphere Networks. “Trilogy does incredibly vital work for people living with mental illness in the Chicago community, and we’re happy to help in any way we can.”

Stratosphere has a long-standing relationship with Trilogy and previously sponsored the organization’s 50th Anniversary Gala, Heart & Compassion Gala, and Spring Into Recovery Gala.

To learn more about the Changing Lives celebration, donate, or purchase tickets, visit the event website. Please direct inquiries to development@trilogyinc.org.

About Stratosphere Networks

Stratosphere Networks helps businesses bypass the traditional sales process and quickly find leading Unified Communications as a Service (UCaaS), Contact Center as a Service (CCaaS), customer experience (CX), digital transformation, business process outsourcing (BPO), managed IT and cybersecurity solutions. Leveraging advanced tools and in-depth knowledge of the technology landscape, our team identifies products and services that position our clients for lasting success. Visit https://www.stratospherenetworks.com for more information.

For more information contact:

Lori Leonardo

847-440-8608

LoriL@stratospherenetworks.com

Share article on social media or email: